Skip to main content
main-content

06-28-2021 | ADA 2021 | Conference coverage | Video

SUSTAIN-FORTE: Doubling the approved semaglutide dose for people with type 2 diabetes

share
SHARE

Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes (3:31).

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions